HTDS hit high of .037 bid,today, from call .013.Another bagger for moon=Taki.Weeeeeeeeeeeeee.
ragingbull.lycos.com
By: moon
05 Nov 2003, 09:11 AM EST
Msg. 767 of 806
Jump to msg. #
HTDS.013news.I will trade this stock and plan to make money.B: Hard To Treat Diseases Incorporated - HTDS - Announces Managem
nt Change
B: Hard To Treat Diseases Incorporated - HTDS - Announces Management Change
DELRAY BEACH, Fla., Nov 5, 2003 (BUSINESS WIRE) -- Hard to Treat Diseases
Incorporated ("HTTD") (Pink Sheets:HTDS) announces today the resignations of Dr.
Ronald Shinn, Ph.D. as President, CEO and Chairman of the Board, Mr. Gerry
Knight, Secretary / Treasurer, Director and Zenaida Shinn, Director in letters
dated October 13, 2003 and mailed on October 15, 2003.
The new President and CEO is Mr. Colm J. King who has an extensive background in
the public arena. Mr. King has held positions at midsize and international
accounting firms as director of SEC auditing and compliance as well as a
consultant to various public companies. He has been CFO of two publicly traded
companies. HTTD and its shareholders will benefit from Mr. King's extensive
experience as a turnaround specialist in moving this company forward. HTTD will
be well represented by Mr. King at the helm. The company will continue to
conduct its daily business.
"I want to assure the shareholders that HTTD will have an open line of
communication with its shareholders and information will not be withheld. I plan
to use press releases to communicate with all shareholders and to keep them
abreast of new developments within the company," said Mr. King. "Please
understand that there are some items that cannot be released until all approvals
and criteria are met."
We also wish to advise shareholders that there could be potential liability
resulting from the resignations of the previous management team. The previous
management team has requested that we rescind our purchases of the companies
that we acquired in May 2003 - Hard to Treat Diseases, Inc. and T-19, Inc. We do
not believe that there are any reasons to rescind these acquisitions and will
vigorously defend any lawsuits relating to this matter.
Hard to Treat Diseases Incorporated ("HTTD") holds the world marketing rights to
T-19(R), a nasal spray in which the active ingredient is Tubercin(R), a patented
immunostimulant under medical patent (US Patent 6,274,356). T-19(R) promotes
good health by enhancing the immune system. Due to the homeopathic nature of
T-19(R), the nasal spray application method does not require FDA approval in the
USA and can be put on the holistic market immediately at relatively low cost.
The T-19(R) Nasal Spray application of TUBERCIN(R) is a very effective way of
delivery as it is absorbed efficiently through the nasal mucous membrane.
Hard to Treat Diseases Incorporated ("HTTD") holds the international marketing
rights, except South Korea, to Tubercin(R), a patented immunostimulant developed
for combating Cancer and Rheumatoid Arthritis under US medical Patent
#6,274,356. The unique properties of Tubercin, unlike other cancer products, are
clearly stated in the abstract of the patent... "Is highly effective in treating
various cancer patients without incurring any adverse side effects."
Hard to Treat Diseases Incorporated ("HTTD") is based in and operates out of
Delray Beach, Florida.
This press release contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended and Section 21E of the
Securities Exchange Act of 1934, as amended. The Company's actual results could
differ materially from those set forth in the forward-looking statements as a
result of the risks set forth in the Company's filings with the Securities and
Exchange Commission, changes in general economic conditions, and changes in the
assumptions used in making such forward-looking statements.
SOURCE: Hard to Treat Diseases Incorporated
CONTACT: Hard to Treat Diseases Incorporated, Delray Beach
Colm King, 561-272-6900
Customize your Business Wire news & multimedia to match your needs.
Get breaking news from companies and organizations worldwide.
Logon for FREE today at www.BusinessWire.com.
Copyright (C) 2003 Business Wire. All rights reserved.
-0-
KEYWORD: FLORIDA
INDUSTRY KEYWORD: MEDICAL
PHARMACEUTICAL
MANAGEMENT
CHANGES
*** end of story *** |
